Literature DB >> 28666826

Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition.

Buranee Kanchanatawan1, Supaksorn Thika1, George Anderson2, Piotr Galecki3, Michael Maes4.   

Abstract

The aim of this study was to assess the neurocognitive correlates of affective symptoms in schizophrenia. Towards this end, 40 healthy controls and 80 schizophrenia patients were investigated with six tests of the Cambridge Neuropsychological Test Automated Battery (CANTAB), assessing spatial working memory, paired-association learning, one touch stocking, rapid visual information (RVP), emotional recognition test and intra/extradimensional set shifting. The Hamilton Depression (HDRS) and Anxiety (HAMA) Rating Scales and the Calgary Depression Scale for Schizophrenia (CDSS) as well as the Positive and Negative Syndrome Scale (PANSS) were also used. There were highly significant associations between all 6 CANTAB tests and HDRS, HAMA and CDSS (except RVP) scores. The most significant items associating with neurocognitive impairments in schizophrenia were self-depreciation (CDSS), fatigue, psychomotor retardation and agitation, psychic and somatic anxiety (HDRS), fears, cognitive symptoms, somatic-muscular, genito-urinary and autonomic symptoms and anxious behavior (HAMA). The selected HDRS and HAMA symptoms indicate fatigue, fears, anxiety, agitation, retardation, somatization and subjective cognitive complaints (SCC) and are therefore labeled "FAARS". Up to 28.8% of the variance in the 6 CANTAB measurements was explained by FAARS, which are better predictors of neurocognitive impairments than the PANSS negative subscale score. Neurocognitive deficits in schizophrenia are best predicted by FAARS combined with difficulties in abstract thinking. In conclusion, depression and anxiety symptoms accompanying the negative and positive symptoms of schizophrenia are associated with neurocognitive deficits indicating disorders in executive functions, attention, visual memory, and social cognition. Neurocognitive deficits in schizophrenia reflect difficulties in abstract thinking and FAARS, including subjective cognitive complaints.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Bipolar; CANTAB; Cognition; Major depression; Schizophrenia

Mesh:

Year:  2017        PMID: 28666826     DOI: 10.1016/j.pnpbp.2017.06.031

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

1.  The Relationship Between the Recognition of Basic Emotions and Negative Symptoms in Individuals With Schizophrenia Spectrum Disorders - An Exploratory Study.

Authors:  Marco Zierhut; Kerem Böge; Niklas Bergmann; Inge Hahne; Alice Braun; Julia Kraft; Thi Minh Tam Ta; Stephan Ripke; Malek Bajbouj; Eric Hahn
Journal:  Front Psychiatry       Date:  2022-04-27       Impact factor: 5.435

2.  In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related to Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Learning Study.

Authors:  Buranee Kanchanatawan; Supaksorn Thika; Sunee Sirivichayakul; André F Carvalho; Michel Geffard; Michael Maes
Journal:  Neurotox Res       Date:  2018-01-29       Impact factor: 3.911

3.  The difference of social cognitive and neurocognitive performance between patients with schizophrenia at different stages and influencing factors.

Authors:  Shengyun Chen; Yaxi Liu; Dennis Liu; Guican Zhang; Xiaoli Wu
Journal:  Schizophr Res Cogn       Date:  2021-02-25

4.  Memantine can protect against inflammation-based cognitive decline in geriatric depression.

Authors:  Kathleen Van Dyk; Prabha Siddarth; Maura Rossetti; Linda M Ercoli; Michaela M Milillo; Helen Lavretsky
Journal:  Brain Behav Immun Health       Date:  2020-11-07

Review 5.  Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.

Authors:  István Laszlovszky; Ágota Barabássy; György Németh
Journal:  Adv Ther       Date:  2021-06-06       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.